TALENTM technology: Grant of EP 2 510 096 by the European Patent Office
Published on November 04, 2014
Paris, November 4, 2014 - Cellectis SA (Alternext: ALCLS.PA), a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CART cells (UCART), is pleased to announce the publication of the grant of European patent EP 2 510 096 by the European Patent Office to the University of Minnesota and Iowa State University Research Foundation Inc., on October 22, 2014.
Cellectis has exclusive rights to this patent under an agreement entered in 2011 with the Regents of the University of Minnesota.
EP 2 510 096 is the first European patent ever granted in the field of TAL-nucleases.